Revised forecast
Fiscal year ending March 2027 · Six months and full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
For the next fiscal year, the company forecasts net sales of ¥106.0 billion, operating income of ¥19.0 billion, ordinary income of ¥20.4 billion, and net income attributable to owners of the parent of ¥13.6 billion. The impact of the situation in the Middle East is expected to be limited, while timely product price revisions will be used to minimize the impact of higher raw material and fuel prices.
Loss on disposal of fixed assets: ¥307 million; loss on sale of fixed assets: ¥2 million; headquarters relocation expenses: ¥62 million; total special losses: ¥371 million (fiscal year ended March 2026)
| Item | Details |
|---|---|
| Net Sales | Not disclosed → Cumulative second-quarter results 52,000 / Full year 106,000（Cumulative second-quarter results 6.5% (versus the same period of the previous year) / Full year 6.0% (versus the previous fiscal year)） |
| Operating profit | Not disclosed → Cumulative second-quarter results 8,800 / Full year 19,000（Cumulative second-quarter results 8.5% (versus the same period of the previous year) / Full year 7.7% (versus the previous fiscal year)） |
| Ordinary income | Not disclosed → Cumulative second-quarter results 9,500 / Full year 20,400（Cumulative second-quarter results 6.6% (versus the same period of the previous year) / Full year 4.0% (versus the previous fiscal year)） |
| Profit attributable to owners of the parent | Not disclosed → Cumulative second-quarter results 6,400 / Full year 13,600（Cumulative second-quarter results -5.3% (versus the same period of the previous year) / Full year -12.0% (versus the previous fiscal year)） |
| Net income per share | Not disclosed → Cumulative second-quarter results 52.10 / Full year 110.70 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Previous-period results | Net sales: ¥99,961 million; operating income: ¥17,634 million; ordinary income: ¥19,608 million; net income attributable to owners of the parent: ¥15,460 million; net income per share: ¥123.96 (fiscal year ended March 2026) |
| Reason for the revision | For the next fiscal year, the company forecasts net sales of ¥106.0 billion, operating income of ¥19.0 billion, ordinary income of ¥20.4 billion, and net income attributable to owners of the parent of ¥13.6 billion. The impact of the situation in the Middle East is expected to be limited, while timely product price revisions will be used to minimize the impact of higher raw material and fuel prices. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets: ¥307 million; loss on sale of fixed assets: ¥2 million; headquarters relocation expenses: ¥62 million; total special losses: ¥371 million (fiscal year ended March 2026) |
| Dividend forecast revision | Not stated as a revision. The forecast for the fiscal year ending March 2027 is ¥14.00 per share at the end of the second quarter, ¥14.00 per share at fiscal year-end, and ¥28.00 per share for the full year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fiscal year ended March 2026, results were affected by the resolution of supply issues and increased sales volumes in basic chemicals, changes in demand for products and pharmaceuticals in functional chemicals and healthcare, cost reductions, and expanded sales. For the fiscal year ending March 2027, the company expects the economy to recover, while assuming risks including the situation in the Middle East and U.S. tariff measures. It plans to address higher raw material and fuel prices by revising product prices.